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PTH-induced osteoblast contraction is mediated by cysteine
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PTH-induced osteoblast contraction is mediated by cysteine proteases.
E-64d, a membrane-permeable cysteine protease inhibitor, was tested
for its ability to inhibit PTH-induced contraction in intact mouse
MC-3T3-El osteoblastic cells. Incubation of MC-3T3-E1 cells with
vehicle (DMSO) or E-64c, a nonpermeant cysteine protease inhibitor, in
the presence or in the absence of PTH had no effects on cAMP
production or on morphology from 0 to 90 minutes after addition. In
contrast, treatment with E-64d markedly attenuated PTH-induced
contraction in these cells. These findings suggest that cysteine pro-
teases, such as the calcium-activated neutral proteases (calpains), are
involved in PTH-induced osteoblastic contraction. The observation that
cysteine protease activity mediates PTH-induced osteoblastic contrac-
tion also suggests that endogenous inhibitors, such as calpastatin, may
also be present in the osteoblast and play a role in the regulation of
stimulus-response coupling in bone. This mechanism may provide
another regulatory point at which bone cells may be pharmacologically
manipulated in clinical situations characterized by excessive bone
resorption.
Parathyroid hormone (PTH)-induced bone resorption plays a
major role in the pathogenesis of renal osteodystrophy [1]. Of
interest has been the observation that osteoblasts, the bone
forming cells, play a central role in PTH-induced bone resorp-
tion [21. Following binding to specific, high-affinity receptors on
the surface of osteoblasts, PTH stimulates the secretion of
soluble products from osteoblasts which modulate the bone
resorptive potential of osteoclasts [3]. In addition, PTH stimu-
lation causes cytoplasmic contraction of the osteoblasts which
effectively exposes more underlying bone matrix to the resorp-
tive activity of the osteoclasts [4—6].
Available information suggests that PTH activates both 3' ,5 '-
cyclic adenosine monophosphate (cAMP)- and calcium-depen-
dent regulatory pathways in osteoblasts [7]. While the intracel-
lular protein targets of cAMP have been extensively
characterized [2, 8, 9], relatively little is known about the
calcium-activated target proteins of PTH in bone cells. Calci-
um-activated processes are known to play critical roles in the
mediation of cytokinetic activities including the contractile
response [10]. While Miller, Wolf and Arnaud demonstrated
that the PTH-activated morphological transformation of the
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osteoblasts was mediated through cAMP-dependent pathways
[6], the possibility that PTH may also induce osteoblast con-
traction through a calcium-dependent, cAMP-independent
mechanism has not been examined.
Cysteine protease inhibitors, such as E-64 and recombinant
human cystatin C, have previously been shown to inhibit bone
resorption in vivo and in vitro in several systems including
isolated osteoclasts [11—14]. Thus, while it is apparent that
cysteine proteases are an important component of the oste-
oclast-mediated aspects of bone resorption, it has not been
previously documented that they may also participate in the
osteoblast-mediated aspects of bone resorption. In this study,
we evaluated the possibility that PTH-induced cytoplasmic
contraction of MC-3T3-E 1 mouse osteoblastic cells in vitro may
involve the participation of cysteine proteases by using the
membrane-permeable cysteine protease inhibitor, E-64d.
Calpain (jcium-activated papain-like) I and II are the major
cytosolic, non-lysosomal cysteine proteases present in a wide
variety of cell types [15]. These enzymes play an important role
in a number of physiological processes which involve irrevers-
ible, calcium-dependent proteolysis of cytoskeletal and mem-
brane proteins, enzymes and receptors [16]. Endogenous sub-
strates of the calpains include myofibrillar proteins (troponin,
myosin, actinin, and filamin), as well as cytoskeletal proteins
(vimentin, desmin, fodrin, tubulin, microtubule-associated pro-
teins, spectrin, and talin) which are important in cytokinesis
[16]. We have recently demonstrated calpain I/Il activity in
MC-3T3-El osteoblastic cells [17] and propose an alternate
mechanism in which these cysteine proteases may mediate
PTH-induced bone resorption through a calcium regulated
pathway.
Methods
Materials
Rat parathyroid hormone (PTH) (1-34) was obtained from
Bachem (Torrance, California, USA). Ham's F12 and Dulbec-
co's modified Eagle's media (DMEM), antibiotics, low-protein
serum replacement (LPSR-1), newborn calf serum (NCS),
glutamine, Mayer's hematoxylin and all routine biochemicals
and buffers were obtained from Sigma Chemical Company (St.
Louis, Missouri, USA). E-64c was purchased from Boehringer
Mannheim (Indianapolis, Indiana, USA), while E-64d was the
gift of Thomas C. Detwiler, Ph.D. (Department of Biochemis-
try, SUNY Health Science Center, Brooklyn, New York,
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USA). Immobilon-P (polyvinyldiene difluoride or PVDF) trans-
fer membrane was obtained from Millipore Corporation (Bed-
ford, Massachusetts, USA). Biotinylated goat anti-rabbit IgG,
avidin DH, and horseradish peroxidase were obtained from
Vector Laboratories (Burlingame, California, USA). Immuno-
histochemical-grade rabbit anti-cAMP IgG was obtained from
Chemicon International (Temecula, California, USA).
Cell culture
MC-3T3-E1 cells were routinely cultured in DMEM supple-
mented with 10% NCS, 2 ms'i glutamine, penicillin-G (100
UIml), and streptomycin (100 gIml) in a humid atmosphere of
95% air, 5% CO2 as previously described [18]. Media were
changed every other day, and the cells were subcultured on a
weekly basis.
PTH treatment
For morphologic studies, MC-3T3-E1 cells were plated at a
density of 100,000 cells/60 mm dish and allowed to adhere
overnight in the media described above. On days 2 to 14 in
culture, representative plates were rinsed with phosphate-
buffered saline (PBS) three times to remove residual serum and
switched to serum-free DMEM supplemented with antibiotics
and 1% LPSR. Immediately prior to the morphologic studies,
these plates were rinsed three times with PBS, preincubated
with vehicle (dimethyl sulfoxide, DMSO), or cysteine protease
inhibitor (50 g/m1 of E-64c or E-64d) in DMEM for five
minutes at 37°C, then observed in presence of PTH 1-34 (4.8
nM) for up to 90 minutes. Cells were photographed on Kodak
Gold 200 multipurpose film using a Zeiss Axiovert 35 micro-
scope fitted with a Nikon MF2 35-mm camera. Representative
fields were photographed and cell number and surface area
covered were determined by image-analysis using JAVA soft-
ware (Jandel Scientific, San Rafael, California, USA).
Cell blotting
Basal and PTH-stimulated cAMP production was measured
by cellular Western blotting as previously described [191 in
parallel cultures using the doses of PTH, cysteine protease
inhibitors, and vehicle outlined above. This method allows
quantitation of the proportion of cells staining positively as well
as providing semiquantitative data regarding the intensity of the
response.
Statistical methods
Numerical analysis of data consisting of means of continuous
variables was done with Student's t-test whereas comparisons
of proportions were accomplished using the chi square test.
Some computations were performed on a Macintosh Ilsi com-
puter using Statview 512 + software (BrainPower, Agoura Hills,
California, USA).
Results
Morphologic assay of osteoblastic contraction
The morphology of MC-3T3-El cells observed for 0, 15 and
30 minutes in the presence of vehicle (A), 4.8 nM PTH (B), 4.8
nM PTH + 50 g!ml E-64d (5 minute preincubation and exper-
imental period) (C) and 50 ig!ml E-64d alone (D) is shown for
representative plates five days after initial plating (Fig. 1).
Under control conditions in the presence of vehicle (DMSO),
the morphology of MC-3T3-E 1 cells did not change during the
90-minute observation period (Fig. 1A). Treatment with 4.8 nM
PTH resulted in marked contraction within five minutes which
reached a maximum by 30 minutes. Representative fields for 0,
15 and 30 minutes are shown in Figure lB. However, simulta-
neous treatment with E-64d, the membrane-permeable cysteine
proteinase inhibitor, and 4.8 nM PTH was associated with a
marked attenuation of the contractile response to PTH treat-
ment which continued for the entire 90 minute period (Fig. 1C).
Treatment with E-64c, the membrane-impermeable cysteine
protease inhibitor, had no effect on MC-3T3-El cell morphol-
ogy (Fig. 2A) and did not attenuate the PTH-induced contrac-
tion (Fig. 2B). Cells initially treated with PTH resumed their
pre-treatment morphology within 30 minutes of reintroduction
of serum-containing media which did not contain exogenous
PTH.
Similar results following treatment with vehicle, PTH, and
inhibitors, alone or in combination, were obtained for cultures
maintained from 2 to about 10 days post-plating, by which time
the cultures had become post-confluent, and PTH-induced
contraction could not readily be documented (data not shown).
Quantitative analysis of the surface area occupied by the cells
indicated that the degree of contraction which was inhibited by
E-64d was approximately 50% under the treatment conditions
used in our studies (Table 1).
Production of cAMP following PTH treatment
Cyclic AMP production following treatment for 90 minutes
with vehicle alone (A), PTH (B), PTH + E-64d (C), and E-64d
alone (D) was assessed by cellular Western blotting in parallel
with the morphologic studies described above. Results of these
studies are shown in Figure 3. Production of cAMP was low
under basal conditions (Fig. 3A). The activity that was present
represents constitutive production plus that activity which
results from the rigorous mechanical treatment (trypsinization,
centrifugation, tituration, and dilution) to which the cells are
subjected during the blotting procedure. Addition of 4.8 flM
PTH markedly stimulated cAMP production, as indicated by
increases in both the proportion of cells exhibiting immunopo-
sitive staining and the relative intensity of staining (Fig. 3B).
Production of cAMP was not inhibited by addition of E-64d in
the presence or absence of PTH (Fig. 3 C and D). Quantitative
analysis of these data is shown in Table 2. The proportion of
cells elaborating cAMP was low under basal conditions and
high following treatment with PTH. The addition of E-64d to
PTH had no effect on the proportion of cells which stained
positively for cAMP (Table 2).
Discussion
Several studies have reported on the effect of PTH on bone
cell morphology. Matthews and Talmage observed marked
morphologic changes in tibial osteocytes/osteoblasts one hour
after PTH (TCA powder) injection into thyroparathyroidecto-
mized rats [5]. Jones and Boyde, using neonatal rat calvarial
organ culture, noted that exposure to parathyroid extract (PTE)
for 24 hours caused a marked elongation and dramatic parallel
realignment of bone cells [4]. Miller, Wolf and Arnaud, using
primary culture of fetal rat calvarial cells, observed that PTH
(1-34) transformed spherical cells into stellate cells [6]. Unlike
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Fig. 1. Morphological response of MC-3T3-EI mouse osteoblastic cells to treatment with PTH and the cysteine protease inhibitor, E-64d. Treated
cells were observed for 90 minutes but maximal response occurred by 30 minutes. Treatments: vehicle (DMSO) control (A); 4.8 nM PTH (B); PTH
+ 50 jig/mi E-64d (C); and E-64d alone (D). Original magnification: 320 x. Reproduction of this figure in color is made possible by a grant from
Procter and Gamble Pharmaceuticals.
O MINUTES
15 MINUTES
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Fig. 2. Morphological response of MC-3T3-E1 mouse osteoblastic cells to treatment with E-64c, a nonpermeant cysteine protease inhibitor, and
PTH. Cells were observed for 90 minutes but maximal response occurred by 30 minutes. Treatments: 50 sg/ml E-64c (A); E-64c + 4.8 flM PTH
(B). Original magnification 320 x.
the previous two studies, morphologic transformation was
followed in "live" cells without fixation [6]. Shape changes
began within 30 minutes and maximum transformation was
observed at 60 to 90 minutes [6]. Thereafter, reversion to
pre-treatment shape began and was complete by three to six
hours [6]. In all these studies morphologic changes were ob-
served qualitatively using models which are expected to contain
heterogeneous bone cell populations.
In the current study, we quantitated the effect of PTH on a
clonal osteogenic cell line, MC-3T3-El, established from neo-
natal mouse calvarial cells. The cell line exhibits high alkaline
phosphatase activity in the resting state and differentiates into
osteoblasts which deposit mineral (hydroxyapatite) in vitro [20].
In this more homogeneous cell population exhibiting the osteo-
blastic phenotype we confirmed a rapid contractile response to
PTH. However, unlike the observations of Miller, Wolf and
Arnaud [6], spontaneous reversion to pre-treatment morphol-
Table 1. Quantitative image analysis of osteoblastic cell contraction
PTH PTH + E-64d
Before After Before After
treatment treatment treatment treatment
Areas 57.2 2.80 21.6 1.27 56.4 2.38 41.7 1.60
Nt' 177 105 199 214
Quantitative image analysis of four photomicrographs from a repre-
sentative experiment in which MC-3T3-E1 osteoblastic cells were
treated with either PTH (4.8 nM) alone or PTH plus E-64d (50 g/ml).
Photomicrographs of the same high power fields before and after
treatment were analyzed. The data are expressed as relative units of
area corresponding to the photomicrograph area in mm2 occupied by
cells in the visual field. Statistical comparisons of the differences
between the means by Student's t-test, PTH (before) vs. PTH + E-64d
(before), P > 0.1; PTH (before) vs. PTH (after), P < 0.005; PTH +
E-64d (before) vs. PTH + E-64d (after), P < 0.005; PTH (after) vs. PTH
+ E-64d (after), P < 0.005.
a Data expressed as the mean cell area standard error of the meanb Number of cells counted
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Fig. 3. Production of cAMP by MC-3T3-El mouse osteoblastic cells in response to treatment with PTH and the thiol protease inhibitor, E-64d.
Generation of cAMP was detected by cellular Western blotting. Treatments were: vehicle (DMSO) control (A); 4.8 nr'i PTH (8); PTH + 50 g/ml
E-64d (C); and E-64d alone (D). Cells were treated for 90 minutes. Nuclei appear as dark grey or black dots whereas positive immunostaining
appears as a more diffuse grey haze around the nucleus. Absolute cell numbers per photographic field vary. Quantitative analysis of these data is
shown in Table 2. Original magnification: 100 x.
ogy did not occur unless the culture was returned to serum- the underlying matrix and could account for the prompt calce-
containing media devoid of added PTH. This rapid osteoblast mic response to PTH administration observed in intact animals
response to PTH would allow immediate osteoclastic access to and humans [21.
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Table 2. Numerical analysis of cellular Western blots
Treatment
Number of cAMP (+) cells % Cells
cAMP (+)Total number of cells counted
A. Vehicle 35/236 14.8%
B. E-64d 21/156 13.5%
C. PTH 293/371 79.0%
D. E-64d + PTH 157/182 86.3%
Numerical analysis of cellular Western blots presented in Figures
3A-D. The cells were treated with vehicle (basal) (A), 50 g/ml E-64d
(B), 4.8 nM PTH (C), or E-64d + PTH (D), blotted and analyzed for
cAMP immunoreactivity. Statistical comparisons of the proportions of
cells staining positively for cAMP (CAMP (+)) by chi square test, basal
vs. E-64d, P> 0.05; basal vs. PTH, P < 0.001; basal vs. E-64d + PTH,
P < 0.001; E-64d vs. PTH, P < 0.001; E-64d vs. E-64d + PTH, P <
0.001; PTH vs. E-64d + PTH, P > 0.05.
While the phenomenon of PTH-induced contraction of the
osteoblast is well documented, the mechanism responsible for
this response is not completely characterized. Miller, Wolf and
Arnaud suggested that the contractile response is mediated
through the well known PTH-induced cAMP pathway [6]. Our
study indicates that the PTH-induced contraction of osteoblasts
is markedly attenuated by treatment with the membrane per-
meable cysteine protease inhibitor, E-64d, but not the nonper-
meant analogue, E-64c. The membrane-penetrating E-64d,
upon entrance into the cell, is rapidly hydrolysed to E-64c
which, being membrane-impermeable, is trapped inside the cell
[21]. E-64c inactivates cysteine proteases by alkylating the
active site cysteine and is 100 to 1000 times more potent than
E-64d [15, 211. Our findings suggest that the contractile re-
sponse of osteoblasts to PTH is mediated through an intracel-
lular cysteine protease system and is not affected by the
presence of extracellular cysteine protease inhibition.
Two features of the above-mentioned observation are of
particular relevance to this study. First, cysteine protease
inhibition did not appear to have any effect on basal and
PTH-induced cAMP production. This suggests that the full
expression of the PTH-induced osteoblast contraction which
has previously been shown to be mediated by cAMP may also
require the presence of intracellular protease activity. Quanti-
tative image analysis suggests that approximately half of the
contractile response to PTFJ can be attributed to E-64d-inhibit-
able cysteine protease activity in intact cells. Second, previous
studies have reported that cysteine protease inhibitors reduce
bone resorption through the inhibition of osteoclastic lysosomal
cysteine proteases released into the extracellular milieu of the
ruffled border region [11—14]. Our study indicates that the
inhibition of the intracellular cysteine proteases in the osteo-
blast can further abrogate bone resorption by attenuating the
PTH-activated contraction of these cells, thus effectively reduc-
ing the exposure of the underlying bone matrix to the action of
osteoclasts.
The best characterized intracellular nonlysosomal cysteine
proteases are the calpains, or calcium-activated neutral pro-
teases (CANP) [10, 15]. We have reported CANP activity in
osteoblastic cells [17]. Calpains exist in two forms distinguished
by sensitivity to [Ca2]1 [10, 23]. Calpain I (p.) has a high affinity
for Ca2 (Ka = 2 to 75 jiM) and calpain 11(m) has a lower
affinity for Ca2 (Ka 0.2 to 0.8 mM) [10, 23]. Calpain I and
II consist of unique 80 k catalytic subunits which share a
common 30 k regulatory subunit [22]. Analysis of gene structure
suggests that the 80k catalytic subunits arose by fusion of genes
for a cysteine protease and calmodulin, resulting in a calcium-
activated cysteine protease, while the 30 k regulatory subunit
contains four EF-hand domains and is structurally related to
calmodulin [22]. (Auto)proteolysis of calpain II significantly
reduces the concentration of Ca2 required for full activation,
and both forms could exhibit activity under basal and hormone
stimulated conditions in vivo [23]. Quantitation of calpain
activity in cells and tissues is complicated by the presence of
endogenous inhibitors, such as calpastatin, and multistep puri-
fication to separate calpastatin and the calpains is frequently
required in order to accurately determine the full activity and
relative levels of these proteases [15]. The necessity for cell
disruption and processing further confounds the interpretation
of the measurements obtained since extracellular and intracel-
lular calcium ion concentrations are equalized by cell lysis.
Under these conditions, the elevated [Ca2]1 and the presence
of activators, such as phospholipids, can lead to (auto)proteol-
ysis of both the calpains and their endogenous inhibitor, calp-
astatin [15]. Our current approach of examining the effects of a
membrane-permeable cysteine protease inhibitor on vital osteo-
blastic cells circumvents the complications associated with cell
disruption. While conclusive proof for the participation of the
calpains in PTH-induced osteoblast contraction awaits a more
quantitative and direct approach, our data on the protease-
dependent osteoblast contraction serve to provide evidence
that cysteine proteases are involved in several aspects of bone
resorption. This regulatory control point may be exploited for
possible therapeutic interventions in the management of renal
osteodystrophy and other clinical conditions manifested by
inappropriate bone resorption.
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